2022 Clinical Development Metabolic Stability Trials 
Metabolite Tales Blog
JULY 5, 2023
Still, of the 34 macrocycles currently in clinical trials, only 18% are de novo designed. Not only this, the reduction in rotatable bonds and consequent reduction in susceptibility to metabolism is an additional benefit [4]. CYP3A4 is involved in clearance to two major metabolites M1 and M2, representing 9.6% Chen et al.,
Metabolite Tales Blog
JULY 5, 2023
Still, of the 34 macrocycles currently in clinical trials, only 18% are de novo designed. Not only this, the reduction in rotatable bonds and consequent reduction in susceptibility to metabolism is an additional benefit [4]. Several metabolites were observed with an S -oxide and an acyl glucuronide being major human metabolites.
Expert insights. Personalized for you.
52 
Let's personalize your content